BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug.

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Bayer Leverkusen have announced the signing of Ernest Poku (21) from AZ Alkmaar for a reported €12m including bonuses. The ...

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Bayer has recently settled thousands of cases over claims the active ingredient in its Roundup weedkiller causes cancer, ...

Bayer Leverkusen are out to begin the Erik ten Hag era with a win as they take on fourth-division side Sonnenhof Großaspach in the DFB Cup first round on Friday (kick-off: 6pm CEST).

Investor concerns that Bayer's earnings were inflated by soccer player transfer fees rather than supported by its core ...